PRIOR AUTHORIZATION (PA) PREPARATION TIPS AND CHECKLIST

A PA MAY BE NECESSARY WHEN AN APPROPRIATE ADULT PATIENT WITH OAB HAS RESTRICTED ACCESS TO TREATMENT WITH GEMTESA

Note: This resource provides information commonly used by payor plans to determine PA. It is intended for reference only and does not guarantee approval. Please be sure to check payor policies for the most up-to-date information.

✓ Gather details beforehand to inform the PA

- Find out the PA requirements from the patient's health plan, including specific forms
- Determine if the health plan necessitates a step edit
- Collect relevant medical records, including chart notes

✓ Provide personal/professional information

- Include patient information, such as full name, address, date of birth, gender, and member ID
- Include provider information, such as full name, specialty, address, National Provider Identifier, and office/fax numbers

✓ Detail diagnosis, medical history, and treatment

- Provide the OAB-related diagnosis and include the appropriate ICD-10-CM code(s) related to OAB (eg, N32.81 Overactive Bladder)[1,*]
- Add historical patient symptoms and tests undertaken, including physical exam and urinalysis[1]
- Document previous and current medication use/failure and rationale for new treatment
- Include recommended treatment dosage and directions
  - One 75-mg GEMTESA tablet taken once daily with or without food. Swallow GEMTESA tablets whole with a glass of water[2]
  - In adults, GEMTESA tablets also may be crushed, mixed with a tablespoon (approximately 15 mL) of applesauce and taken immediately with a glass of water[2]

CoverMyMeds® is available to provide support for the PA process, and electronically connect providers, pharmacists, and health plans. Learn more at CoverMyMeds.com.

*Nothing in this document is intended to serve as reimbursement advice. The decision about which code to report must be made by the provider/physician considering the clinical facts, circumstances, and applicable coding rules.

ICD-10-CM=*International Classification of Diseases, Tenth Revision, Clinical Modification*; ICS=International Continence Society; OAB=overactive bladder.

INDICATIONS AND USAGE

GEMTESA® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product.

Please see reverse for additional Important Safety Information and accompanying full Prescribing Information.

GEMTESA® (vibegron) 75 mg tablets

EXAMPLE PA CHECKLIST FOR GEMTESA

Patient Information

First Name_____ Middle Name_____ Last Name_____ Suffix_____

Address_____ City_____ State_____ ZIP_____

Date of Birth____/___/_____ Gender_____ Member ID_____

Is the patient on Medicare? ◯ Yes ◯ No Is the patient in long-term care? ◯ Yes ◯ No

◯ Initiation of therapy ◯ Continuation of therapy

Diagnosis

◯ Urge urinary incontinence ◯ Urgency ◯ Urinary frequency ◯ Other_____

ICD-10-CM Code(s)			

Treatment History

Has the patient tried and failed any over-the-counter incontinence products? ◯ Yes ◯ No

Has the patient tried and failed any behavioral interventions, such as pelvic floor muscle training or bladder training? ◯ Yes ◯ No

Has the patient tried and failed a first-line urinary antispasmodic? ◯ Yes ◯ No

Treatment or Medication & Dosage	Date Started	Date Ended	Notes

Additional Medical Information

Include any necessary supporting documentation for other medical conditions the patient may have that influenced your prescribing decision (eg, high blood pressure, prolonged QT interval, dysphagia, cognitive impairment, etc).

Personalized Support for the GEMTESA Treatment Journey

Patient CONNECT Support

The Urovant Sciences Patient Connect Support Program can help appropriate patients access GEMTESA with tools such as prior authorization support through CoverMyMeds.

Learn how CoverMyMeds® Can Help With Prior Authorizations

Live Support via chatbox at CoverMyMeds.com or, via phone at 1-833-UROVANT,
Monday–Friday, 8:00 AM –11:00 PM ET; Saturday, 8:00 AM – 6:00 PM ET

The CoverMyMeds® website is neither owned nor controlled by Urovant Sciences. Urovant Sciences is not responsible for the content on the CoverMyMeds® website.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS & PRECAUTIONS

Urinary Retention

Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction and patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

Please see accompanying full Prescribing Information.

References: 1. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. *J Urol.* 2012;188(6)(suppl):2455-2463. **2.** GEMTESA [Prescribing Information]. Irvine, CA: Urovant Sciences, Inc.

UROVANT SCIENCES

GEMTESA® (vibegron) 75 mg tablets